Session » Vasculitis – ANCA-Associated Poster I

Date: Monday, October 22, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1758

A 24 Month Analysis of Rituximab Safety and Efficacy in Eosinophilic Granulomatosis with Polyangiitis

9:00AM-11:00AM: Abstract Number: 1766

Abdominal Adipose Tissue Predicts Incident Major Cardiovascular Events in Systemic Necrotizing Vasculitis Patients: Data from a Prospective Cohort Study on 120 Patients

9:00AM-11:00AM: Abstract Number: 1757

An Economic Systematic Literature Review of Eosinophilic Granulomatosis with Polyangiitis

9:00AM-11:00AM: Abstract Number: 1752

Asthma in Eosinophilic Granulomatosis with Polyangiitis Treated with Rituximab

9:00AM-11:00AM: Abstract Number: 1755

Burden of Illness Associated with Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss Syndrome): Evidence from a Managed Care Database in the United States

9:00AM-11:00AM: Abstract Number: 1765

Cerebrospinal Fluid Biomarker of Disease Activity: Significance in ANCA-Related Hypertrophic Pachymeningitis

9:00AM-11:00AM: Abstract Number: 1763

Characterizing the Gut and Plasma Metabolomes in Patients with ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1754

Clinical and Economic Characteristics of Patients Diagnosed with Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss Syndrome) in the United States

9:00AM-11:00AM: Abstract Number: 1769

Efficacy and Safety of Biomimic Rituximab in Granulomatosis with Polyangiitis – Experience from a Single Tertiary Care Centre in India

9:00AM-11:00AM: Abstract Number: 1745

Efficacy of Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss) Treatments According to the Type of Manifestations Based on Analysis of 376 Patients

9:00AM-11:00AM: Abstract Number: 1759

Eosinophilic Granulomatosis with Polyangiitis: A Monocentric Cohort Analysis of Manifestations and Relapses of ANCA-Positive and ANCA-Negative Patients

9:00AM-11:00AM: Abstract Number: 1761

Evaluation of the Functional Activity of Endothelial Progenitor Cells in Patients with ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1760

Fungal Composition of the Nasal Mucosa in Patients with Granulomatosis with Polyangiitis

9:00AM-11:00AM: Abstract Number: 1746

Impact of Interstitial Lung Disease on the Long-Term Survival in 76 Japanese Patients with Microscopic Polyangiitis

9:00AM-11:00AM: Abstract Number: 1751

Interstitial Lung Disease during ANCA-Associated Vasculitis: A Poor-Prognosis Factor

9:00AM-11:00AM: Abstract Number: 1753

Interstitial Lung Disease in ANCA-Associated Vasculitis Defines a Unique Subgroup of Patients at High Risk for Respiratory Death: A Cluster Analysis

9:00AM-11:00AM: Abstract Number: 1748

Interstitial Lung Disease in ANCA-Positive Vasculitis Patients

9:00AM-11:00AM: Abstract Number: 1768

Kidney Involvement, Poor Performance Status, and Higher Cumulative Dose of Glucocorticoid Are the Risk Factors of the Discontinuation of Immunosuppressant in Patients with Antineutrophil Cytoplasmic Antibody Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1747

Long-Term Outcomes of Patients with Nonsevere Eosinophilic Granulomatosis with Polyangiitis Given Azathioprine and Glucocorticoids for Remission Induction

9:00AM-11:00AM: Abstract Number: 1749

Long-Term Renal Outcome in Pulmonary-Limited Microscopic Polyangiitis

9:00AM-11:00AM: Abstract Number: 1771

Long-Term Survival of Renal Transplantation in Rapidly Progressive Glomerulonephritis (RPGN). Study of 43 Cases from a Single Center

9:00AM-11:00AM: Abstract Number: 1767

Occurrence and Etiology of Gastrointestinal Perforation in Patients with Vasculitis

9:00AM-11:00AM: Abstract Number: 1762

Plasma iC3b Level As a Biomarker of Disease Relapse in ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1750

Rheumatoid Factor Titer Is Inversely Correlated with ANCA Titer and Relates to Characteristic Manifestations in Patients with Eosinophilic Granulomatosis with Polyangiitis

9:00AM-11:00AM: Abstract Number: 1770

Subglottic Stenosis and Endobronchial Disease in Granulomatosis with Polyangiitis

9:00AM-11:00AM: Abstract Number: 1756

Systematic Review of the Clinical Effectiveness of Treatments in Eosinophilic Granulomatosis with Polyangiitis

9:00AM-11:00AM: Abstract Number: 1764

The Utility of Serum Angiopoietin-1 and Angiopoietin-2 in Patients with Anti-Neutrophil Cytoplasmic Autoantibody-Associated Vasculitis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].